CagriSema vs Tirzepatide: Key Differences

CagriSema and tirzepatide are built on different receptor targets: CagriSema combines an amylin analog (cagrilintide) with a GLP-1 analog (semaglutide), while tirzepatide is a single molecule that activates both the GIP and GLP-1 receptors. Both have been studied in large randomized trials for weight management, but they arrived there through different pharmacology.

How are these two compounds different

Tirzepatide is one peptide that binds two receptors — GIP and GLP-1 — which is why it is often called a "dual agonist." Jastreboff et al., N Engl J Med 2022 reported the SURMOUNT-1 trial results for weekly tirzepatide in adults with obesity, the data set that underlies its approval pathway.

CagriSema is a combination product: two separate peptides, cagrilintide and semaglutide, co-administered to act on amylin and GLP-1 receptors at the same time. The REDEFINE 1 trial tested this combination in adults with overweight or obesity (Garvey et al., N Engl J Med 2025), and REDEFINE 2 tested it in adults with overweight or obesity and type 2 diabetes (Davies et al., N Engl J Med 2025).

What the trials actually measured

REDEFINE 1 and REDEFINE 2 are the two pivotal CagriSema trials the FDA approval pathway, if one is pursued, would rely on. REDEFINE 1 enrolled adults with overweight or obesity without diabetes and reported body weight outcomes over the trial period (Garvey et al., N Engl J Med 2025). REDEFINE 2 enrolled adults with overweight or obesity who also had type 2 diabetes, a population where glycemic measures were tracked alongside weight (Davies et al., N Engl J Med 2025).

SURMOUNT-1 is the comparable pivotal trial for tirzepatide: it tested weekly dosing in adults with obesity and reported body weight change as a primary outcome (Jastreboff et al., N Engl J Med 2022). That trial, together with others in the SURMOUNT program, supported tirzepatide's path to FDA approval as Zepbound for chronic weight management (FDA, 2023) and as Mounjaro for type 2 diabetes.

A reader comparing the two molecules on paper is really comparing two different approaches to the same receptor family: tirzepatide engineers both activities into a single peptide, while CagriSema pairs two peptides with complementary mechanisms — amylin signaling from cagrilintide, GLP-1 signaling from semaglutide.

Is either one approved by the FDA

Tirzepatide is approved by the FDA, sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management (FDA, 2023). CagriSema has not received FDA approval; as of this writing it remains in phase 3 development, with REDEFINE 1 and REDEFINE 2 as its two reported pivotal trials.

PeptoClinic's cagrilintide, semaglutide, and tirzepatide vials are not Mounjaro, Zepbound, Ozempic, or Wegovy, and none of them is approved by the FDA. These are not compounded versions of the branded drugs either — the FDA has published specific concerns about unapproved and compounded GLP-1 products marketed for weight loss, which is worth reading before assuming any unbranded version carries the same review history as the approved drug (FDA, concerns about unapproved GLP-1 drugs).

What about a triple-mechanism option

Readers comparing CagriSema and tirzepatide sometimes land on a third candidate: retatrutide, which activates GIP, GLP-1, and glucagon receptors in one molecule. It has been studied in phase 2 trials for obesity (Jastreboff et al., N Engl J Med 2023) and type 2 diabetes (Rosenstock et al., Lancet 2023), and a phase 3 obesity trial has since been reported (Jastreboff et al., N Engl J Med 2026). Like CagriSema, retatrutide is not approved by the FDA.

PeptoClinic's full catalog lists all three — cagrilintide, semaglutide, and tirzepatide, along with retatrutide — with current pricing for US orders.